Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.
about
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancerPredictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signaturesThe potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study.Proliferation markers in tumours: interpretation and clinical value.Prognostic and predictive value of p53 and p21 in breast cancer.The relationship between prognostic and predictive factors in the management of breast cancer.Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.DNA repair and personalized breast cancer therapyEvaluation and Validation of Neo-Adjuvant Response Index (NRI) and It's Correlation with Various Predictive Biomarkers and RECIST in Locally Advanced Breast CancerEvaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.HER-2/neu and topoisomerase IIalpha in breast cancer.Evaluation of biomarker changes after administration of various neoadjuvant chemotherapies in breast cancer.Can ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy?Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical reviewKi-67 biomarker in breast cancer of Indian womenNeoadjuvant chemotherapy in breast cancer.Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?Immunohistochemical assessment of primary breast tumors and metachronous brain metastases, with particular regard to differences in the expression of biological markers and prognosisCorrelation between the expression of S100A4 and the efficacy of TAC neoadjuvant chemotherapy in breast cancer.USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancerPrognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer.Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer.Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breastOestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancerThe mitochondrial transport protein SLC25A43 affects drug efficacy and drug-induced cell cycle arrest in breast cancer cell linesCell killing and resistance in pre-operative breast cancer chemotherapyNeo-adjuvant hormonal therapy.Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome.Different methods of pretreatment Ki-67 labeling index evaluation in core biopsies of breast cancer patients treated with neoadjuvant chemotherapy and their relation to response to therapy.Effect of vinca alkaloids on ERalpha levels and estradiol-induced responses in MCF-7 cells.Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer.Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.Glutathione-s-transferase-pi expression in early breast cancer: association with outcome and response to chemotherapy.Prognostic value of proliferation markers expression in breast cancer.Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen.Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer.Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?
P2860
Q24597847-DFDDBDE1-A443-4711-A1FC-DAAC61DC9882Q24812541-5CEC8692-3822-4AA5-B509-97BC8B51F618Q33480671-C9AB1C66-1F2B-4A40-842E-69C860A0F04FQ33534215-1A93B839-2B77-42B8-9BDF-919AAB10DC08Q33538430-AE4F3B53-EFF0-473A-A577-CF38B2D342F4Q33538455-1A4F7BB4-6490-4678-AE69-C081E49A3FB7Q33903965-FBE7B3BC-AF7D-407F-AACD-D55FFF509C45Q34234936-5DA53D9D-D691-4E29-8FF0-7F03F6A65D91Q34534308-7F6D0800-AE6E-42FE-AEED-45CFA4B2DC16Q35012858-C72685BF-C0E4-4AFB-81E9-371730190224Q35130680-74A52154-20ED-4105-A18D-68A81E2AAC1FQ35145309-B21C24D7-2273-4D1F-BA66-9430BD853F7CQ35160045-BFB8617E-A5FA-4BE6-B91A-2F4460ED87ACQ35252217-9977758F-412A-4916-BCB7-AFBAD6D83210Q35809752-B4391317-CC47-4242-B56A-00CD6B813CAEQ35904441-FBD513E7-E85F-4A4E-B8F0-1D91BEBC61CAQ35913434-41361612-5801-4C4D-8448-B257F00B0044Q36001232-B941125A-E0CD-4B1B-BB2D-0C72318C99C5Q36175746-2A1A50FC-68D8-4D8C-B312-E0669F82A4D1Q36244120-E838BB38-4B10-4CE3-AADF-443C046501A8Q36334801-7A947B06-28E0-4D30-8B31-CF0C32E358F2Q36599308-CF8CE8BD-6746-40A1-BC33-0C1665CE4678Q36621469-88DE0852-DBAF-483D-A910-B8CD2D060614Q36648223-42200EE3-1F3C-41C2-8EB8-7A331F77B3DDQ36648472-2B1F6AE5-5556-4747-8518-47280227C197Q36678684-07628136-6C7D-47F2-9C04-746199F6F5EBQ36695226-FA009E3D-0879-484A-A32A-6E89FB8CCC63Q36753310-FA5EA53A-B9B8-4A93-A1BB-1FB59B032053Q36812607-C6F2DC4F-C8F3-492B-82AC-F13EE3E3C973Q37121880-98656C51-F6C7-41BB-966E-D532C5C0444AQ37354971-4AEED1C3-31CB-4914-A8DD-4958C961C83AQ40195184-B21FA51A-C16D-4792-993D-5EA51A973383Q40300786-62F30C31-1F6F-4904-BFD5-08E180036CD8Q40362934-99FBACED-D2EE-4C1E-8E46-A67B9AC697B4Q40458598-D60D6DDE-E9D8-4F84-B82D-3A24F2B6021FQ43139246-D485CDE8-0300-48F4-A427-80CE0BF472E6Q43692538-F5E3BC11-EA95-42AB-9CA0-E2D0D3A97A52Q43785972-0A53A1A5-41E0-4163-AA24-9F952E74D054Q44704125-BEDBE6C0-7791-4447-A260-145A4AAD4ED9Q44879611-94030BD3-5D3F-4B4A-B4F2-AA76B0F880A4
P2860
Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Primary chemotherapy in breast ...... -erbB-2, MiB1, pS2 and GST pi.
@ast
Primary chemotherapy in breast ...... -erbB-2, MiB1, pS2 and GST pi.
@en
type
label
Primary chemotherapy in breast ...... -erbB-2, MiB1, pS2 and GST pi.
@ast
Primary chemotherapy in breast ...... -erbB-2, MiB1, pS2 and GST pi.
@en
prefLabel
Primary chemotherapy in breast ...... -erbB-2, MiB1, pS2 and GST pi.
@ast
Primary chemotherapy in breast ...... -erbB-2, MiB1, pS2 and GST pi.
@en
P2093
P2860
P356
P1476
Primary chemotherapy in breast ...... -erbB-2, MiB1, pS2 and GST pi.
@en
P2093
F Bonichon
G MacGrogan
I de Mascarel
J M Coindre
P2860
P2888
P304
P356
10.1038/BJC.1996.565
P407
P577
1996-11-01T00:00:00Z